JP2006501252A - Ｄｎａ変異原性ダメージの修復 - Google Patents
Ｄｎａ変異原性ダメージの修復 Download PDFInfo
- Publication number
- JP2006501252A JP2006501252A JP2004533066A JP2004533066A JP2006501252A JP 2006501252 A JP2006501252 A JP 2006501252A JP 2004533066 A JP2004533066 A JP 2004533066A JP 2004533066 A JP2004533066 A JP 2004533066A JP 2006501252 A JP2006501252 A JP 2006501252A
- Authority
- JP
- Japan
- Prior art keywords
- aryl
- alkyl
- skin
- hydrogen
- arylalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000006378 damage Effects 0.000 title claims abstract description 16
- 231100000219 mutagenic Toxicity 0.000 title claims abstract description 12
- 230000003505 mutagenic effect Effects 0.000 title claims abstract description 12
- 230000008439 repair process Effects 0.000 title claims description 11
- ADFCQWZHKCXPAJ-GFCCVEGCSA-N equol Chemical compound C1=CC(O)=CC=C1[C@@H]1CC2=CC=C(O)C=C2OC1 ADFCQWZHKCXPAJ-GFCCVEGCSA-N 0.000 claims abstract description 39
- 235000019126 equol Nutrition 0.000 claims abstract description 39
- ADFCQWZHKCXPAJ-UHFFFAOYSA-N indofine Natural products C1=CC(O)=CC=C1C1CC2=CC=C(O)C=C2OC1 ADFCQWZHKCXPAJ-UHFFFAOYSA-N 0.000 claims abstract description 39
- 238000000034 method Methods 0.000 claims abstract description 26
- ZZUBHVMHNVYXRR-UHFFFAOYSA-N 3-(4-hydroxyphenyl)-2h-chromen-7-ol Chemical compound C1=CC(O)=CC=C1C1=CC2=CC=C(O)C=C2OC1 ZZUBHVMHNVYXRR-UHFFFAOYSA-N 0.000 claims abstract description 24
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 10
- 208000000453 Skin Neoplasms Diseases 0.000 claims abstract description 9
- 201000000849 skin cancer Diseases 0.000 claims abstract description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 33
- 125000003118 aryl group Chemical group 0.000 claims description 33
- 229910052739 hydrogen Inorganic materials 0.000 claims description 32
- 239000001257 hydrogen Substances 0.000 claims description 32
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 32
- 239000000203 mixture Substances 0.000 claims description 32
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 claims description 27
- 102000003792 Metallothionein Human genes 0.000 claims description 27
- 108090000157 Metallothionein Proteins 0.000 claims description 27
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 21
- 150000001875 compounds Chemical class 0.000 claims description 20
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims description 18
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims description 18
- 125000001188 haloalkyl group Chemical group 0.000 claims description 15
- 108020004414 DNA Proteins 0.000 claims description 12
- 125000003342 alkenyl group Chemical group 0.000 claims description 9
- 125000003282 alkyl amino group Chemical group 0.000 claims description 9
- 150000001413 amino acids Chemical class 0.000 claims description 9
- 125000004432 carbon atom Chemical group C* 0.000 claims description 9
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 9
- 239000002537 cosmetic Substances 0.000 claims description 8
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 6
- 125000004414 alkyl thio group Chemical group 0.000 claims description 6
- 125000000304 alkynyl group Chemical group 0.000 claims description 6
- 125000001475 halogen functional group Chemical group 0.000 claims description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 6
- 239000000516 sunscreening agent Substances 0.000 claims description 6
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims description 6
- 230000003247 decreasing effect Effects 0.000 claims description 5
- 230000001737 promoting effect Effects 0.000 claims description 5
- -1 amino, thio Chemical group 0.000 claims description 4
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 4
- UPUOLJWYFICKJI-UHFFFAOYSA-N cyclobutane;pyrimidine Chemical class C1CCC1.C1=CN=CN=C1 UPUOLJWYFICKJI-UHFFFAOYSA-N 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 230000000475 sunscreen effect Effects 0.000 claims description 4
- 125000004171 alkoxy aryl group Chemical group 0.000 claims description 3
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 3
- 238000010586 diagram Methods 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 125000003386 piperidinyl group Chemical group 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 230000000699 topical effect Effects 0.000 claims description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 6
- 208000003373 basosquamous carcinoma Diseases 0.000 claims 2
- CNNBJLXLTIKXGJ-UHFFFAOYSA-N 3-phenyl-2h-chromene Chemical compound C1OC2=CC=CC=C2C=C1C1=CC=CC=C1 CNNBJLXLTIKXGJ-UHFFFAOYSA-N 0.000 abstract description 9
- NNQSGBRGJHSRFN-UHFFFAOYSA-N isoflavan Chemical class C1OC2=CC=CC=C2CC1C1=CC=CC=C1 NNQSGBRGJHSRFN-UHFFFAOYSA-N 0.000 abstract description 8
- 210000003491 skin Anatomy 0.000 description 57
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 33
- 239000006210 lotion Substances 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 12
- 238000007388 punch biopsy Methods 0.000 description 12
- 239000003981 vehicle Substances 0.000 description 11
- 210000002615 epidermis Anatomy 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 230000005855 radiation Effects 0.000 description 5
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 4
- 206010041823 squamous cell carcinoma Diseases 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 4
- 230000005778 DNA damage Effects 0.000 description 3
- 231100000277 DNA damage Toxicity 0.000 description 3
- 230000033616 DNA repair Effects 0.000 description 3
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000004224 protection Effects 0.000 description 3
- 238000007390 skin biopsy Methods 0.000 description 3
- 241000282412 Homo Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108091093078 Pyrimidine dimer Proteins 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 229960001679 octinoxate Drugs 0.000 description 2
- 229960001173 oxybenzone Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000013635 pyrimidine dimer Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
- QYIOFABFKUOIBV-UHFFFAOYSA-N CC(O1)=C(C)OC1=O Chemical compound CC(O1)=C(C)OC1=O QYIOFABFKUOIBV-UHFFFAOYSA-N 0.000 description 1
- YSNPLDIMMPWRFK-UHFFFAOYSA-N CC1(OC(C)=C(C)O1)I Chemical compound CC1(OC(C)=C(C)O1)I YSNPLDIMMPWRFK-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 239000012623 DNA damaging agent Substances 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 1
- 230000008649 adaptation response Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940114081 cinnamate Drugs 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 235000002324 isoflavanes Nutrition 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000025600 response to UV Effects 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000005477 standard model Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- 239000000717 tumor promoter Substances 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Birds (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2002951271A AU2002951271A0 (en) | 2002-09-06 | 2002-09-06 | Repair of dna mutagenic damage |
| PCT/AU2003/001152 WO2004022023A1 (en) | 2002-09-06 | 2003-09-05 | Repair of dna mutagenic damage |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006501252A true JP2006501252A (ja) | 2006-01-12 |
| JP2006501252A5 JP2006501252A5 (https=) | 2006-10-26 |
Family
ID=27671591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004533066A Pending JP2006501252A (ja) | 2002-09-06 | 2003-09-05 | Ｄｎａ変異原性ダメージの修復 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20060153781A1 (https=) |
| EP (1) | EP1534232A4 (https=) |
| JP (1) | JP2006501252A (https=) |
| CN (1) | CN1688285A (https=) |
| AU (1) | AU2002951271A0 (https=) |
| CA (1) | CA2497823A1 (https=) |
| CZ (1) | CZ2005136A3 (https=) |
| MX (1) | MXPA05002519A (https=) |
| NO (1) | NO20051605D0 (https=) |
| TR (1) | TR200500749T2 (https=) |
| WO (1) | WO2004022023A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006508058A (ja) * | 2002-09-23 | 2006-03-09 | ノボジェン・リサーチ・プロプライエタリー・リミテッド | 皮膚光老化および光線性損傷の治療 |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104643057A (zh) | 2002-07-24 | 2015-05-27 | 儿童医院医疗中心 | 含有对映体牛尿酚的组合物和产物及其用途 |
| US8668914B2 (en) | 2002-07-24 | 2014-03-11 | Brigham Young University | Use of equol for treating skin diseases |
| WO2004039327A2 (en) | 2002-10-29 | 2004-05-13 | Colorado State University Research Foundation | Use of equol for treating androgen mediated diseases |
| US8580846B2 (en) | 2002-10-29 | 2013-11-12 | Brigham Young University | Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders |
| CA2738510A1 (en) * | 2008-07-30 | 2010-02-04 | Novogen Research Pty Ltd | 6-substituted isoflavonoid compounds and uses thereof |
| HRP20240793T1 (hr) | 2018-04-18 | 2024-09-13 | Constellation Pharmaceuticals, Inc. | Modulatori enzima koji modificiraju metil, njihovi pripravci i upotreba |
| EP3797108B1 (en) | 2018-05-21 | 2022-07-20 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| LT4003532T (lt) | 2019-07-24 | 2024-11-11 | Constellation Pharmaceuticals, Inc. | 7-chlor-2- (4-(3-metoksiazetidin-1-il)cikloheksil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-okso-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioksol-5-karboksamido kristalinės formos |
| CN114831981A (zh) * | 2021-02-02 | 2022-08-02 | 上海交通大学 | 一种ERβ选择性激动剂在抗肿瘤中的应用 |
| CN117599041B (zh) * | 2024-01-22 | 2024-05-03 | 中国人民解放军军事科学院军事医学研究院 | 去氢雌马酚及其衍生物作为新型辐射防护剂和细胞保护剂的医药用途 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998008503A1 (en) * | 1996-08-30 | 1998-03-05 | Novogen Research Pty. Ltd. | Therapeutic methods and compositions involving isoflavones |
| WO1999036050A1 (en) * | 1997-12-24 | 1999-07-22 | Novogen Research Pty. Ltd. | Compositions and method for protecting skin from uv induced immunosuppression and skin damage |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPP868599A0 (en) * | 1999-02-15 | 1999-03-11 | Novogen Research Pty Ltd | Production of isoflavone derivatives |
| DE10121375B4 (de) * | 2001-05-02 | 2014-01-16 | Beiersdorf Ag | Verwendung von Isoflavonoiden in kosmetischen oder dermatologischen Zubereitungen zur Prophylaxe vor und Behandlung von sensibler Haut |
| DE10122342A1 (de) * | 2001-05-09 | 2002-11-14 | Beiersdorf Ag | Verwendung von Isoflavonen in kosmetischen oder dermatologischen Zubereitungen |
-
2002
- 2002-09-06 AU AU2002951271A patent/AU2002951271A0/en not_active Abandoned
-
2003
- 2003-09-05 EP EP03793484A patent/EP1534232A4/en not_active Withdrawn
- 2003-09-05 JP JP2004533066A patent/JP2006501252A/ja active Pending
- 2003-09-05 CN CNA038240114A patent/CN1688285A/zh active Pending
- 2003-09-05 CA CA002497823A patent/CA2497823A1/en not_active Abandoned
- 2003-09-05 TR TR2005/00749T patent/TR200500749T2/xx unknown
- 2003-09-05 US US10/526,830 patent/US20060153781A1/en not_active Abandoned
- 2003-09-05 CZ CZ20050136A patent/CZ2005136A3/cs unknown
- 2003-09-05 MX MXPA05002519A patent/MXPA05002519A/es active IP Right Grant
- 2003-09-05 WO PCT/AU2003/001152 patent/WO2004022023A1/en not_active Ceased
-
2005
- 2005-03-30 NO NO20051605A patent/NO20051605D0/no not_active Application Discontinuation
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998008503A1 (en) * | 1996-08-30 | 1998-03-05 | Novogen Research Pty. Ltd. | Therapeutic methods and compositions involving isoflavones |
| JP2001500480A (ja) * | 1996-08-30 | 2001-01-16 | ノボケン リサーチ ピーティーワイ リミテッド | イソフラボン類を含有する治療方法及び組成物 |
| WO1999036050A1 (en) * | 1997-12-24 | 1999-07-22 | Novogen Research Pty. Ltd. | Compositions and method for protecting skin from uv induced immunosuppression and skin damage |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006508058A (ja) * | 2002-09-23 | 2006-03-09 | ノボジェン・リサーチ・プロプライエタリー・リミテッド | 皮膚光老化および光線性損傷の治療 |
Also Published As
| Publication number | Publication date |
|---|---|
| NO20051605L (no) | 2005-03-30 |
| NO20051605D0 (no) | 2005-03-30 |
| TR200500749T2 (tr) | 2005-10-21 |
| EP1534232A4 (en) | 2008-12-24 |
| CZ2005136A3 (cs) | 2006-04-12 |
| AU2002951271A0 (en) | 2002-09-19 |
| EP1534232A1 (en) | 2005-06-01 |
| CN1688285A (zh) | 2005-10-26 |
| CA2497823A1 (en) | 2004-03-18 |
| WO2004022023A1 (en) | 2004-03-18 |
| US20060153781A1 (en) | 2006-07-13 |
| MXPA05002519A (es) | 2005-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU716131B2 (en) | Genistein as a preventive against ultraviolet induced skin photodamage and cancer | |
| US8940343B2 (en) | Personal care composition | |
| JP2000516249A (ja) | 皮膚日焼け剤組成物および皮膚日焼け方法 | |
| JP2006501252A (ja) | Ｄｎａ変異原性ダメージの修復 | |
| US20050271606A1 (en) | Composition for treating inflammation which contains zinc pyrrolidonecarboxylate | |
| JP2003520221A (ja) | Ｕｖ誘導免疫抑制の治療 | |
| JPH10101543A (ja) | チロシナーゼ活性阻害剤及び化粧料 | |
| JP2002536313A (ja) | 角質層機能の増強のための硫酸コレステロール組成物 | |
| US20060153782A1 (en) | Skin photoageing and actinic damage treatment | |
| AU2003257264B2 (en) | Repair of DNA mutagenic damage | |
| JPH1072330A (ja) | チロシナーゼ活性阻害剤及び化粧料 | |
| CN117164668B (zh) | 多肽化合物、其组合物及其用途 | |
| JP2001131051A (ja) | ＡＧＥｓ分解作用を有する老化肌防御、改善化粧料 | |
| JP3432033B2 (ja) | 光老化防止剤及びこれを含有する皮膚化粧料 | |
| JP2010138153A (ja) | 紫外線予防用の皮膚外用剤 | |
| JP4129475B2 (ja) | コラーゲン合成促進剤及びこれを含む皮膚外用剤組成物 | |
| US9539189B2 (en) | Photoprotective personal care composition | |
| JPH072640A (ja) | 紫外線障害防御外用剤 | |
| JP2006022090A (ja) | ピロリドンカルボン酸亜鉛塩から成る炎症抑制剤 | |
| JP3113407B2 (ja) | 化粧料 | |
| KR100769579B1 (ko) | 피부 주름 개선용 화장료 조성물 | |
| JPH10226642A (ja) | 皮膚増殖疾患の治療剤 | |
| JP5578997B2 (ja) | がん化学療法誘発脱毛に対する抗脱毛用組成物 | |
| JP2001509129A (ja) | 皮膚の老化過程を抑制するための化粧品組成物及び方法 | |
| JPH06321763A (ja) | 美白剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060905 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060905 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100309 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100803 |